Exclusive Summary

• 1) Long off-patent, mature global generic market, and the 1.2 g bulk vial targets hospital IV compounding needs; 2) Large inpatient demand for severe Gram-negative/Pseudomonas infections aligns with guideline-supported combination therapy; 3) US registration provides quality and regulatory credibility to accelerate multi-country market entry and distribution; 4) Despite many generics, intermittent supply tightness and limited coverage of large vials create entry points via reliable supply and SKU differentiation; 5) Significant cost savings versus originator, with further savings from reduced compounding time and consumables using the 1.2 g vial.